论文部分内容阅读
目的:探讨消癌平注射液对二乙基亚硝胺复制肝癌模型大鼠血清IL-17水平的影响。方法:选取Wistar雄性大80只,随机分为空白对照组、模型组、苦参素组以及消癌平组,各20只。各组均给予二乙基亚硝胺溶液灌胃腹腔注射建立肝癌模型,并给予相应的药物治疗。对大鼠肿瘤体积,瘤重,抑瘤率及组织病理学形态,肝脏指数,脾脏指数,血清ALT、AST、GGT水平,血清细胞因子水平以及外周血T淋巴细胞亚群水平进行检测。结果:治疗后,与模型对照组比较,(1)各组大鼠肿瘤体积、瘤重较低,其中消癌平组<苦参素组(P<0.05);消癌平组抑瘤率高于苦参素组(P<0.05);(2)各组大鼠肝脏指数、脾脏指数较低,其中消癌平组<苦参素组(P<0.05);(3)各组大鼠血清ALT、AST、GGT水平较低,其中消癌平组<苦参素组(P<0.05);(4)各组大鼠血清IL-17、IL-6、TNF-α水平较低,其中消癌平组<苦参素组(P<0.05);各组大鼠血清IL-2水平较高,其中消癌平组>苦参素组(P<0.05);(5)各组大鼠外周血CD3+、CD4+T淋巴细胞亚群及CD4+/CD8+水平较高,其中消癌平组>苦参素组(P<0.05)。结论:消癌平注射液能够明显抑制二乙基亚硝胺复制肝癌模型大鼠肿瘤生长,能降低肝脏指数、脾脏指数,改善大鼠肝功能,降低大鼠血清IL-17、IL-6、TNF-α水平,提高血清IL-2水平,提高免疫功能。
Objective: To investigate the effect of Xiaokangping injection on serum IL-17 level in diethylnitrosamine-induced liver cancer model rats. Methods: Eighty Wistar male rats were randomly divided into blank control group, model group, oxymatrine group and Xiaocanping group, 20 in each. All groups were given diethylnitrosamine solution intraperitoneal injection of liver cancer model, and given the appropriate drug treatment. Tumor volume, tumor weight, tumor inhibition rate and histopathology, liver index, spleen index, serum ALT, AST, GGT levels, serum cytokines levels and peripheral blood T lymphocyte subsets were detected. Results: After treatment, compared with the model control group, (1) The tumor volume and the tumor weight of rats in each group were lower than that in the control group (P <0.05); the tumor inhibition rate (P <0.05). (2) The liver index and spleen index of rats in each group were lower than those in the matrine group (P <0.05); (3) The levels of ALT, AST and GGT were lower, and the levels of IL-17, IL-6 and TNF-α in serum were lower in the hypokalemia group (P <0.05); (4) (P <0.05); (2) The level of IL-2 in serum of rats in each group was significantly higher than that in the control group (P <0.05) Blood CD3 +, CD4 + T lymphocyte subsets and CD4 + / CD8 + levels were higher, with Xiaojianping> oxymatrine (P <0.05). Conclusion: Xiao-Jin-Ping Injection can significantly inhibit the growth of rat model of diethylnitrosamine-induced hepatocellular carcinoma, reduce the index of liver and spleen, improve the hepatic function of rats, decrease the levels of IL-17, IL-6, TNF-α levels, increase serum IL-2 levels, improve immune function.